FALMINA Drug Patent Profile
✉ Email this page to a colleague
When do Falmina patents expire, and when can generic versions of Falmina launch?
Falmina is a drug marketed by Novast Labs Ltd and is included in one NDA.
The generic ingredient in FALMINA is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.
Summary for FALMINA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Formulation / Manufacturing: | see details |
Drug Sales Revenues: | Drug sales revenues for FALMINA |
DailyMed Link: | FALMINA at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for FALMINA
US Patents and Regulatory Information for FALMINA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novast Labs Ltd | FALMINA | ethinyl estradiol; levonorgestrel | TABLET;ORAL-28 | 090721-001 | Mar 28, 2012 | AB1 | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |